Skip to main content

BENIGN AND MALIGNANT MYOEPITHELIOMA OF SALIVARY-GLAND - AN IMMUNOHISTOCHEMICAL EVALUATION

Buy Article:

$42.00 + tax (Refund Policy)

Three myoepitheliomas (MEOs) derived from the salivary glands were examined immunohistochemically. Proliferating cell nuclear antigen (PCNA)-positive cells were very rare (less than 2% of all tumor cells) in localized tumors of case 1 (epithelioid) (E-oid) cells) and case 2 (plasmacytoid) (P-toid) cells with a small number of spindle-shaped cells), but the percentage of PCNA-positive cells was high (21.8%) in case 3 (clear cells) exhibiting bone destruction. Strong c-myc expression was detected in all the tumors, but p53 or c-erbB-2 protein was not detected in any of the cases. More than half of the clear cells were positive for epidermal growth factor (EGF), while fewer tumor cells in cases 1 and 2 expressed EGF. A few tumor cells in cases 2 and 3 were positive for EGF-receptor (R). Keratin was most prominent in the E-oid cells, The P-toid cells were most strongly positive for S-100 protein followed by the E-oid and clear cells. More than half of the spindle-shaped cells and one-third of the E-oid cells were positive for alpha-smooth muscle actin (alpha-SMA), but less than 5% of the clear cells and none of the P-toid cells were positive for alpha-SMA. These results suggest that tumor cells in MEO are heterogenous and have different proliferation activities.

Document Type: Research Article

Affiliations: KOCHI MED SCH,DEPT ORAL SURG,NANKOKU,KOCHI 783,JAPAN.

Publication date: 01 June 1995

More about this publication?
  • The International Journal of Oncology provides an international forum for the publication of the latest, cutting-edge research in the broad area of oncology and cancer treatment. The journal accepts original high quality works and reviews on all aspects of oncology research including carcinogenesis, metastasis, epidemiology, chemotherapy and viral oncology. Through fair and efficient peer review, the journal is dedicated to publishing top tier research in the field, offering authors rapid publication as well as high standards of copy-editing and production. The International Journal of Oncology is published on a monthly basis in both print and early online.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content